177Lu-FA-DOTA-PEG-PLGA

177Lu-FA-DOTA-PEG-PLGA is a nanoparticle-based radiopharmaceutical designed as a targeted, sustained-release drug delivery system for cancer therapy—specifically for ovarian cancer. It consists of a poly(lactic-co-glycolic acid) (PLGA) nanoparticle core functionalized with polyethylene glycol (PEG), equipped with DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) as a chelator for the radioactive isotope lutetium-177 (^177Lu), and conjugated to folic acid (FA) as a targeting ligand. The radiolabeled nanoparticles exhibit long circulation times and low renal clearance, and are administered via intraperitoneal injection to exploit folate receptor-mediated uptake by ovarian cancer cells. The mechanism of action combines targeted beta-radiation therapy (via ^177Lu emission causing localized cell death) with increased tumor specificity from FA targeting. Preclinical studies have shown antitumor efficacy in relevant mouse models[1][3][4][5].